ERBB2 and breast cancer: Specifically, Abravanel and colleagues performed a computational interrogation of data from 4463 BC patients across 17 individual datasets and genetically engineered mouse models for HER2/neu-targeted therapy; the researchers clearly elucidated that Notch signaling remains activated in a subset of dormant tumor cells after HER2 inhibition and promotes BC recurrence [93].